Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barry Jacobson

Obstetrics & Gynecology Glen Mills, PA Medical Doctor

NPI 1275679250 CMS profile 148074

1020 Baltimore Pike Ste 220, Glen Mills, PA 19342

Open in the dashboard

General payments

$301,861

945 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$642 paid to institutions, not to them · program year 2019

Through program year 2025, Barry Jacobson of Glen Mills, PA is reported in the CMS Open Payments database as having received $301,861 across 945 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $642 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,077 105
2024 General $25,639 124
2023 General $18,260 104
2022 General $20,811 97
2021 General $33,018 122
2020 General $18,600 79
2019 General $166,457 314

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barry Jacobson
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Barry Jacobson were reported at $19,077. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Barry Jacobson Obstetrics & Gynecology median Middle half National median
2019 $166,457 $172 $62–$391 $163
2020 $18,600 $94 $36–$222 $114
2021 $33,018 $136 $42–$369 $132
2022 $20,811 $160 $50–$433 $149
2023 $18,260 $169 $56–$423 $160
2024 $25,639 $152 $50–$371 $164
2025 $19,077 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $223,959 531 payments
  2. Radius Health, Inc. $75,991 306 payments
  3. Alexion Pharmaceuticals, Inc. $496 20 payments
  4. Almatica Pharma LLC $276 23 payments
  5. TherapeuticsMD, Inc. $203 15 payments
  6. AbbVie, Inc. $203 10 payments
  7. Kyowa Kirin, Inc. $145 10 payments
  8. UCB, Inc. $102 5 payments
  9. Sage Therapeutics, Inc. $68 3 payments
  10. Ultragenyx Pharmaceutical Inc. $52 3 payments
  11. Other $366 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $227,843 136 payments
  2. Travel and Lodging $47,463 168 payments
  3. Food and Beverage $17,262 635 payments
  4. Consulting Fee $9,275 5 payments
  5. Gift $18 1 payment
Products named General payments · program years 2019–2025
  1. EVENITY $113,718 317 payments
  2. Prolia $101,969 295 payments
  3. Tymlos Endocrinology $73,594 202 payments
  4. Tymlos Endocrinology $1,599 79 payments
  5. STRENSIQ $330 15 payments
  6. TERIPARATIDE $321 25 payments
  7. Crysvita $145 10 payments
  8. IMVEXXY $142 12 payments
  9. ANNOVERA $123 11 payments
  10. VRAYLAR $78 3 payments
  11. Other $763 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

727

Median for Obstetrics & Gynecology: 65

Drug cost

$245,236

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

25.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tymlos Abaloparatide Brand 62 $185,321
Prolia Denosumab Brand 19 $32,345
Raloxifene Hcl Generic 328 $17,325
Estradiol (Twice Weekly) Estradiol Brand 50 $5,457
Risedronate Sodium Generic 19 $1,301
Chlorthalidone Generic 51 $909
Progesterone Progesterone, Micronized Brand 18 $900
Estradiol (Once Weekly) Estradiol Brand 14 $789
Hydrochlorothiazide Generic 143 $725
Vitamin D2 Ergocalciferol (Vitamin D2) Brand 23 $164

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$3,989,845

Of which drugs: $3,816,456

Medicare patients

1,839

Average age 75

Services billed

365,565

1,681 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
High blood pressure 63%
Arthritis 49%
Depression 23%
Ischemic heart disease 20%
Diabetes 18%
Cancer 18%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, romosozumab-aqqg, 1 mg J3111 Office 268 296,101 $2,532,700
Injection, denosumab, 1 mg J0897 Office 661 62,340 $1,271,000
Injection, zoledronic acid, 1 mg J3489 Office 568 2,845 $12,654

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $23,932
$23,932 — 296,101
Tymlos
  • Radius Health, Inc. $708
$708 62 —
Prolia
  • Amgen Inc. $220
$220 19 62,340
TERIPARATIDE
  • Almatica Pharma LLC $132
  • Alvogen Inc $23
$155 — —
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

945 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record